Since Evofos treatment is associated with DNA damage under hypoxia, we anticipated that this may further contribute to the cGAS-STING pathway and elicit type I IFN signaling cascades, enhancing the anti-tumor activity of NK cells and thereby improving treatment outcomes in breast cancer. The gene discussed is STING1; the disease is breast carcinoma.